- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-239/20: Action brought on 30 April 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA)
ECLI:EU:UNKNOWN:62020TN0239
62020TN0239
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
22.6.2020
EN
Official Journal of the European Union
C 209/37
(Case T-239/20)
(2020/C 209/48)
Language in which the application was lodged: German
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)
Details of the proceedings before EUIPO
Applicant for the trade mark at issue: Applicant
Trade mark at issue: Application for EU word mark RUXXIMLA — Application for registration No 17 865 742
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 in Case R 1879/2019-4
Form of order sought
The applicant claims that the Court should:
—annul the contested decision;
—order EUIPO to pay the costs, including the costs of the appeal proceedings.
Plea in law
—Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.